ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: With ALK-positive ALCL patients excluded, the estimated CR rate for PTCL patients receiving anthracycline-based chemotherapy (n = 1,191) was 50.1% (95% CI 44.9–55.3%).